Neue Suche | Kongressdetail
mail
Druckansicht
 
 

6th Gene Therapy for Rare Disorders 2023

Evvnt Promotion / evvnt
-
20.03.2023 - 23.03.2023  Sheraton Boston Hotel, 39 Dalton St, 02199 Boston, USA
Time: 8:00 am to 5:00 pm
 
Kongressthemen
2022 has been a landmark year for the global gene therapy space. With August came the green light for bluebird bio's Zynteglo in the US, the first FDA approval for a gene therapy in over three years. Hot off its heels we saw the accelerated approval of another bluebird bio product, Skysona. Overseas, July and August brought EMA approvals for PTC Therapeutics' Upstaza and BioMarin's Roctavian, the first gene therapies for AADC deficiency and Haemophilia A respectively.
Wissenschaftliche Fach-Gesellschaft
Hanson Wade
Anmerkungen
Speakers: Faraz Ali, Chief Executive Officer, Tenaya Therapeutics, Deborah Ascheim, Chief Medical Officer, Stridebio, Eduard Ayuso, Chief Executive and Technology Officer, DiNAQOR, Sudha Babu, Regulatory CMC Leader, Spark Therapeutics and More
 

Anfragen und Anmeldung:

https://go.evvnt.com/1439816-2?pid=4832
Frau Emily Birt
 
Kategorien
Gesundheitsversorgung, Public Health
Sprache
Englisch
Kongressgebühr
USD 2999.00 - USD 7095.00
Teilnehmer erwartet
1000
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
 
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."

Alumni Club Medizinische Universität WienCentro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioCenter of ExcellenceAnästhesie in Entwicklungsländern e. V.European Public Health Association (EUPHA)Österreichisches Rotes KreuzÄrzte der WeltÖsterreichische Gesellschaft für Public Health